Based on the earnings transcript for Amgen Inc., the company reported strong Q1 financial results with a 15% year-over-year growth in U.S. business and 10% international growth at constant currency. Key highlights include the approval of Corlanor for chronic heart failure, the launch of BLINCYTO for acute lymphoblastic leukemia, and the on-body injector for Neulasta. Management also raised their 2015 earnings guidance. The stock is likely to see a positive impact due to the strong performance and the company's strategic focus on innovation and cost savings. However, short-term concerns may arise from potential patent infringement cases and competitive pressures in certain markets.

**Rating:** 1